瑞舒伐他汀与阿托伐他汀治疗早发冠心病急性心肌梗死疗效对比

Comparative Effect of Rosuvastatin and Atorvastatin in Treating Premature Coronary Heart Disease and Acute Myocardial Infarction

目的比较瑞舒伐他汀与阿托伐他汀治疗早发冠状动脉粥样硬化性心脏病(简称冠心病)急性心肌梗死患者的临床疗效。方法依照入院号单双顺序将早发冠心病急性心肌梗死患者182例分为观察组和对照组,各91例。观察组患者给予瑞舒伐他汀治疗,对照组患者给予阿托伐他汀治疗。结果治疗后,两组患者血脂、左心室射血分数(LVEF)、动脉内皮舒张比例(FMD)和超敏C反应蛋白(hs-CRP)水平均明显改善,且观察组改善幅度更大(P<0.05);两组心血管事件发生率均相对较低,且组间比较无明显差异(P>0.05)。结论瑞舒伐他汀治疗早发冠心病急性心肌梗死的临床疗效较阿托伐他汀更佳,临床可优先选用。

Objective To compare the effect of rosuvastatin and atorvastatin for treating patients with premature coronary heart disease and acute myocardial infarction（ PCHDAMI）. Methods Totally 182 patients with PCHDAMI were divided into the observation group and the control group according to the single and double order of admission number,91 cases in each group. The observation group was treated with rosuvastatin,while the control group was treated with atorvastatin. Results After treatment,the levels of blood lipids,LVEF,FMD and hs-CRP in the two groups were significantly improved,and the observation group was improved more obviously（ P 0. 05）.The incidence rate of cardiovascular events in the two groups was relatively low,and there was no significant difference between the two groups（ P 0. 05）. Conclusion Compare with atorvastatin,revasvastatin is more effective in the treatment of PCHDAMI,which can be selected firstly in the clinical.